Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden
J. Logman (),
Bart Heeg,
Johan Herlitz and
Ben Hout
Applied Health Economics and Health Policy, 2010, vol. 8, issue 4, 265 pages
Abstract:
When considering the cost-effectiveness categorization as proposed by the Swedish National Board of Health and Welfare, clopidogrel appears to be associated with costs per QALY that range from intermediate in the total CAPRIE population to low in high-risk atherosclerotic patients. Copyright Adis Data Information BV 2010
Date: 2010
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)
Downloads: (external link)
http://hdl.handle.net/10.2165/11535520-000000000-00000 (text/html)
Access to full text is restricted to subscribers.
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:8:y:2010:i:4:p:251-265
Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258
DOI: 10.2165/11535520-000000000-00000
Access Statistics for this article
Applied Health Economics and Health Policy is currently edited by Timothy Wrightson
More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().